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IMPACT OF RET PROTO-ONCOGENE ANALYSIS ON
THE CLINICAL MANAGEMENT OF MULTIPLE
ENDOCRINE NEOPLASIA TYPE 2
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Rodrigo de Almeida Toledo, and Delmar Muniz Lourenço Júnior
Toledo SPA, Cortina MA, Toledo RA, Lourenço, DM. Impact of RET proto-oncogene analysis on the clinical management
of multiple endocrine neoplasia type 2. Clinics. 2006:61(1);59-70.
Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant disease characterized by the presence of medullary
thyroid carcinoma, primary hyperparathyroidism, and pheochromocytoma. Multiple endocrine neoplasia type 2 is still an
underdiagnosed, or late-diagnosed condition in many areas of the world. Since 1993, when the first missense RET proto-oncogene
(RET) mutations were reported in MEN2, up to 46 different RET-causing disease mutations have been described. Since a strong
genotype-phenotype correlation exists for MEN2, the detection of RET mutations has produced a major impact in early recognition
and treatment of MTC and MEN2. Presently, RET mutation analysis should be performed for all MEN2 cases and their at-risk
familial relatives. Further, prophylactic total thyroidectomy is indicated in all cases harboring activating gametic RET mutations.
In most RET mutation carriers, prophylactic total thyroidectomy is indicated at ages as early as a few months to 4 years of age,
promoting longer survival and improvement of quality of life or even definitive cure. We discuss the large impact of RET proto-
oncogene analysis on the clinical management of MEN2 and the role of early RET molecular DNA diagnosis in providing clinicians
and surgeons with valuable information that enables them to indicate early total thyroidectomy.
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INTRODUCTION
Multiple endocrine neoplasia type 2 (MEN2) is associated
with the occurrence of 3 inherited endocrine tumors: medul-
lary thyroid carcinoma (MTC), primary hyperparathyroidism
(HPT), and pheochromocytoma (PHEO). Multiple endocrine
neoplasia type 2 is transmitted by an autosomal dominant
gene, which imposes the need of genetic screening of all fam-
ily members at risk having inherited a predisposition to this
condition. The 3 neoplasias involved are derived from neural
crest cells, such as C thyroid cells, parathyroid oxyphilic and
chief cells, and chromaffin cells of the adrenal medulla. Sym-
pathetic, parasympathetic, and enteric ganglia and the urogeni-
tal tract have been also reported as expressing high levels of
several hormonal and nonhormonal substances produced by
the affected glands.1–13,18–20
Despite all efforts performed towards the management
of MEN2, this condition is still an underdiagnosed, or late-
diagnosed disease in many areas of the world. Presently,
molecular DNA diagnosis to identify RET mutations is man-
datory for all MEN2 cases and for their relatives at risk for
a predisposition to MEN2. This diagnostic procedure is turn-
ing out to be a fundamental tool in early MEN2 diagnosis,
enabling correct therapeutic surgical management.12
MOLECULAR MEDICINE
In 1986, with the identification of DNA polymorphisms
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in chromosome 10 in large MEN2 genealogies, the study of
the RET proto-oncogene gained further interest.10 Transfection
DNA studies of several MTC tumors revealed important foci
of proliferation in NIH-3T3 cells, represented by the presence
of different genetic DNA sequences.10 Among these sequences,
one  – RET (rearranged during transfection) – was present in
all tumor specimens. Soon afterwards, the RET sequence was
localized in the chromosome band 10q11.2.10, 13–15 The RET
gene has 60 kb of the human genome spread through 21 exons,
with 60 to 287 base pairs (bp), having a 24 kb intron between
the first and second exons and encoding a protein of approxi-
mately 1,100 amino acids.13,16 In 1993, Mulligan et al and
Donnis-Keller et al (1993) identified the first missense muta-
tions in the RET extracellular RETdomain in patients with
MTC and MEN2.21,22
RET is the only gene that has been associated with
MEN2, and gametic mutation in this proto-oncogene has
been extensively studied. Management of MEN2 using
DNA sequencing information represents an excellent ex-
ample of how molecular DNA diagnosis may improve clini-
cal management.1,3,6,8,13,23
CLASSIFICATION
Table 1 summarizes the accepted classification of
MEN2, as suggested by the international consensus on
MEN.1 This classification is based on clinical pictures of
affected MEN2 patients.
Thyroid cancer is a relatively rare event comprising
0.6% and 1.6% of all carcinomas affecting men and
women, respectively.24 Medullary thyroid carcinoma com-
prises 10% of all thyroid cancers, presenting as sporadic
(75%) or inherited (25%) forms. Multiple endocrine neo-
plasia type 2 has an estimated prevalence of 1 in 30,000
individuals, and more than 90% of RET carriers will de-
velop MTC.1,8,25 The international consensus on MEN es-
timates that 95% of MEN2 patients have a detectable RET
mutation. Mutations in exons 10, 11, and 16 are present in
90% to 95% of cases.1
Multiple endocrine neoplasia type 2A comprises 75%
of all MEN2 cases. In MEN2A, MTC is prevalent in al-
most 100% of patients, whereas PHEO (50%) and HPT
(20%–30%) are less frequently expressed. The mean age
of clinical diagnosis of MEN2A is 20 to 40 years, but this
should soon decrease, as new young RET mutation carri-
ers are recognized and treated earlier in life.8
The familial form of MTC (FMTC) comprises 20% of
all MEN2 cases, and it is characterized by the presence of
MTC in the absence of both PHEO and HPT, both in in-
dex cases and affected family members. Usually in FMTC,
MTC tends to present less aggressive behavior and better
prognosis than in MEN2A or MEN2B.13,26
Five percent (5%) of MEN2 cases have the phenotype
of MEN2B, the most aggressive form of MTC. This form is
characterized by the association of MTC, PHEO, marfanoid
habitus, and mucosal neuromas (lips, tongue, eyebrows, and
intestinal tract), whereas the presence of HPT is very rare.13
Medullary thyroid carcinoma in MEN2B usually appears
very early, usually before 12 months of age.8,27
MEDULLARY THYROID CARCINOMA (MTC)
Affected families usually have several members with
MTC.8 Ever since molecular diagnosis has been performed,
increasing incidences and prevalences of inherited forms
of MTC have been reported. Familial forms of MTC are
constitutive events that lead to bilateral, multicentric thy-
roid cancer. Among several bioactive substances secreted
by thyroid C cells, calcitonin is the most representative and
the best tumor marker for MTC.4,9
Thyroid C-cell hyperplasia is usually the earlier histo-
logic abnormality in MTC and represents a premalignant
stage. It initially occurs as small foci, progressing to nodu-
lar diffuse hyperplasias that may evolve to focal and finally
to metastatic MTC.28–32 The usual clinical presentation of
MTC is a solitary thyroid nodule.28–32 At the stage of pal-
pable thyroid nodules, MTC measures at least 1 cm, and
50% of patients already have local neck lymph node
metastases and more rarely lung, liver, and bone
metastases.33,34 It has been suggested that routine calcitonin
measurements should be performed in all patients with
solid thyroid nodules, since this procedure would permit
presurgical diagnosis of the sporadic form of MTC as well
Table 01 - Phenotypic classification of MEN2 (Adapted
from ref.1, 13)
Multiple endocrine neoplasia2A (1): Families with medullary thyroid
carcinoma, pheochromocytoma and hyperparatyroidism phenotype
Multiple endocrine neoplasia2A (2): Families with medullary thyroid
carcinoma and pheochromocytoma phenotype in at least one at risk relative
Multiple endocrine neoplasia2A (3): Families with medullary thyroid
carcinoma and hyperparatyroidism phenotype in at least one at risk relative
Multiple endocrine neoplasia2B: Families with medullary thyroid
carcinoma, associated or not with pheochromocytoma and muscular / skeletal
abnormalities and mucosal neuromas
Familial medullary thyroid carcinoma: Families only with medullary
thyroid carcinoma phenotype in at least four at risk relatives
Others: Families with less than four relatives with medullary thyroid
carcinoma, pheochromocytoma and hyperparatyroidism phenotype. In this
group are included partially documented families
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as in familial MTC index cases, permitting the establish-
ment of an adequate surgical plan.35,36 Fine-needle biopsy
followed by immunocytochemistry for calcitonin is also
helpful for the presurgical diagnosis of MTC.1,11,12,37–40 To-
tal thyroidectomy associated with extensive resection of
neck lymph nodes is the only effective treatment for MTC,
as the tumor is usually resistant to iodo-, chemo-, and ra-
diotherapy.1,11,12 In early diagnosed cases, C-cell hyperpla-
sia is predominant, and neck lymph node resection may be
less massive.1,11,12
Genetic sequencing of MTC has resulted in dramatically
lower mortality rates. Before Genetic sequencing was avail-
able, mortality rates for MEN2 were up to 20%, whereas
after RET mutation analysis, mortality has been as low as
5% in some samples.1
PHEOCHROMOCYTOMA (PHEO)
Five to fifteen percent of all PHEOs are associated with
MEN2, and most of them (90%) are benign. Pheochromo-
cytomas associated with MEN2 are usually located on the
adrenals (90%), but extra-adrenal cases have been reported.1
Most tumors (50%–80%) are bilateral. Patients with PHEO/
MEN2 present a pretumoral stage characterized by nodu-
lar or diffuse hyperplasia of chromaffin adrenal cells.1,41–48
The diagnosis of PHEO is usually accomplished after the
recognition of MTC (40%–50%); however, it may occur
before or synchronously with MTC diagnosis.1,41 Thus, RET
analysis should be considered in all PHEO cases.1
Notably, the possibility of an undiagnosed PHEO must
be ruled out in all MTC patients before surgery to avoid
the intrasurgical risk of an adrenal hypertensive crisis. Since
a contralateral tumor may appear many years after the first
diagnosis, PHEO/MEN2 patients need long-term follow-up.
Image studies with MIBG (metaiodobenzylguanidine) and
serum/urinary measurements of catecholamines are useful
in this task.1,41
HYPERPARATHYROIDISM (HPT)
Hyperparathyroidism associated with MEN2 (HPT/
MEN2) results from a hyperplastic process of parathyroid
chief cells involving the 4 parathyroid glands. In most HPT/
MEN2 cases (68%), associated adenomas have been also
reported.1,49 Primary HPT associated with MEN2 is a mild
disease presenting slightly elevated concentrations of PTH
and calcium. Several measurements may be needed to en-
able the biochemical diagnosis of HPT.1 In early-diagnosed
MEN2 cases, HPT tends to be asymptomatic. Late-diag-
nosed cases are usually symptomatic, and renal stones are
usually reported as the first clinical symptom. Osteoporo-
sis may occur in such cases. During neck surgery for MTC
in MEN2 cases, enlarged parathyroid glands are frequently
found.1
Two surgical approaches have been used for HPT in
MEN2. In the first approach, the 4 parathyroid glands are
removed and half of a gland is implanted in the
nondominant forearm. In the other approach, 3 1/2 glands
are removed. Postsurgical euparathyroidism is less often
achieved in HPT/MEN2 than in sporadic primary HPT, and
its recurrence rate may be high.1,49 When HPT is present,
parathyroidectomy and total thyroidectomy are usually per-
formed during the same surgical stage.50
Prior to 1993, i.e., before the advent of genetic analy-
sis for RET, all individuals at risk for MTC, PHEO, and
HPT underwent annual screening (from 6 years of age).
This procedure usually included measurements of basal and
stimulated calcitonin, serum and urinary catecholamines,
calcium, and PTH. RET genetic analysis is indicated for
all patients with MTC or PHEO.1 In apparently sporadic
HPT, in the absence of other clinical suspicion for heredi-
tary MEN2, analysis for RET is not usually performed.1
HIRSCHSPRUNG DISEASE (HSCR)
A nonendocrine entity such as congenital megacolon or
Hirschsprung disease (HSCR) has been described in asso-
ciation with gametic inactivating RET mutations and MEN2
cases. This disorder is due to an embryonic defect in the
enteric nervous system. In HSCR associated with MEN2,
myenteric and submucosal plexi are affected in extensive
areas of the distal enteric tube. Most patients present with
intestinal obstruction and constipation. Colectomy is fre-
quently performed at early ages in order to correct intesti-
nal transit.31,51
MOLECULAR ASPECTS
The RET proto-oncogene encodes for a tyrosine kinase
cell membrane receptor. The extracellular domain of this
protein is rich in cysteine residues, and it is encoded by
the first 10 exons of RET. Exon 11 encodes for the trans-
membrane domain, and the 2 intracellular domains of the
protein are encoded by 10 other exons.8,36,52,53
The RET extracellular domain includes coding for a
cadherin-binding site that is important in intercellular
signaling. Extracellular cysteines play an important role in
receptor dimerization. At least 10 RET isoforms have been
reported as result of 5’ and 3’ splicing of exon 21; how-
ever, their physiological function still partially un-
known.8,36,53
The protein encoded by RET plays an important role
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in embryologic migration and development of neural crest-
derived cells, such as thyroid C cells, chromaffin adrenal
cells, sympathetic, parasympathetic, and enteric ganglia
cells, as well as in urogenital tract.13 The RET proto-
oncogene is also expressed in parathyroid cells derived
from branchial arches. Binding proteins such as GDNF
(glial cell line-derived neurotrophic factor) and its receptor,
GFRα-1 (GDNF family receptor alpha one) interact with
the RET-encoded extracellular protein, promoting cell sur-
vival of central and peripheral neurons. The RET proto-
oncogene also plays an essential role in renal and enteric
neural development.13,54,55
Once coupled, ligands and their respective receptors
give rise to a ligand-receptor complex that promotes RET
receptor monomer dimerization through disulfite bonds.
Intracellular tyrosine residues are self-phosphorylated. This
process is followed by a complex signaling pathway in
which mitotic-activating protein kinases (MAPKs) amplify
signaling pathways to cell nuclei, promoting cell mobility
and survival.6,35,56
The same dimerization process occurs independently of
ligand binding when activating RET germline mutations
(constitutive mutation) are present in the RET extracellu-
lar domain, favoring the development of the neoplastic phe-
notypes. RET mutations encode for the intracellular pro-
tein that leads to disturbances in the substrate catalytic core
affinity, favoring the appearance of the neoplastic proc-
ess.6,35,56
Biochemical and transfection studies of tyrosine kinase
have revealed differential RET expressions at the cell mem-
brane level. Thus, cysteine residues next to the 5’ region
(such as mutant codons 609 and 611) present lower pro-
tein expression compared to codon 634 mutations, located
next to the transmembrane domain. The potency of cell
neoplastic transformation of codon 634 RET mutations is
clearly higher than that occurring in codons 609 and 611.
This finding may be due to modulation of expression of
mature RET-encoded protein receptors at the cell mem-
brane, where most of the RET-encoded protein expression
occurs.56,57 Thus, most patients with MEN2 who harbor RET
634 mutations will have thyroid, adrenal, and parathyroid
tumors, whereas patients with 609 or 611 mutations will
present only thyroid cancer. Further, tissue-specific sensi-
tivity may also be modulated by codon-specific RET mu-
tations. Tissue sensitivity is therefore high in thyroid tis-
sue, intermediate in the adrenals, and low in parathyroid
glands.3 These observations may also explain why activat-
ing RET mutations are usually associated with MEN2,
whereas inactivating RET mutations are associated with
HSCR. Mutations in codons 618 and 620 usually result in
RET-encoded receptor amounts sufficient to transform thy-
roid and possibly adrenal cells, but insufficient to produce
disturbances in normal intestinal gangliogenesis.
Hirschsprung disease may be considered a polygenic dis-
ease, because RET, GDNF, endothelin receptor-2 genes, and
genes located at 9q31 and 22q11 bands are involved.6,8
GENOTYPE-PHENOTYPE CORRELATIONS
Multiple endocrine neoplasia type 2A (MEN2A)
The genotype-phenotype correlations in MEN2 are sum-
marized in Table 2. The vast majority of MEN2A cases
(98%) harbors a missense RET mutation, primarily in exon
10 and 11 and in codons 609, 611, 618, 620, 630, and 634,
which comprise a small 25-amino-acid domain.3 Rarely,
small insertions in codons 635 and 637 have been reported.
Codon 634 is involved in 85% of MEN2A mutations; 52%
of them have a Cys634Arg mutation, and 26% present the
Cys634Tyr mutation. Further, MTC tumor aggressiveness
induced by these 2 mutations differ: metastases tend to be
more frequent and early in Cys634Arg cases, as compared
to Cys634Tyr cases.1,13,58,59
In relatives of patients presenting an increased incidence
of HPT and the absence of PHEO, a 12 bp duplication was
found between codons 634 and 635, corresponding to 4
amino acids and co-segregated with a Cys634Arg muta-
tion.8,13 Recently, Nunes et al, of our laboratory, described
a case with double RET mutations (Val648Ile/
Cys634Arg).52,60 In this family, 2 siblings were Val648Ile
carriers and so far have presented neither clinical nor bio-
chemical abnormalities compatible with MEN2A. The
other 2 affected siblings presented the usual Cys634Arg
RET mutation and early classical MTC presentation. The
father presented a rare phenotype of MEN2A associated
with an ectopic ACTH-producing PHEO. He was an ob-
ligatory carrier of the double RET mutation. The MEN2A
in this specific case had a relatively mild presentation.52,60
Mutations in the RET intracellular protein receptor do-
main RET in codons 790 and 804 are rarely associated with
MEN2A. Mutations associated with codon 804 are frequent
in FMTC. In most of these cases, thyroid tumor tends to
present a late onset, slow course, and low aggressiveness,
when compared to phenotypes presenting RET extracellu-
lar-domain mutations. These patients may exhibit incom-
plete neoplastic transformation induced by the 804 muta-
tion; however, aggressive MTC tumors and even death due
to MTC have been reported in cases harboring codon 804
mutations.8,61
Hirschsprung disease has been described in association
with MEN2A or FMTC cases that are associated with mu-
tations primarily in codons 609, 611, 618, and 620.8,62,63
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FAMILIAL MEDULLARY THYROID CARCINOMA
(FMTC)
Most FMTC cases (85%) present RET mutations in
exons 10 and 11. The Cys618Ser genotype is found in 33%
of cases; the Cys634Tyr genotype is found in 30% cases;
whereas, the Cys634Arg genotype is rarely associated with
this phenotype.1,8 Mutations in codons 609, 611, and 620
and those of Glu768Asp, Val804Leu, and Val804Met oc-
curring in tyrosine kinase domains are accepted to be re-
lated to FMTC, even though they may also occur in
MEN2A. Other mutations in RET tyrosine kinase domains,
such as in codons 790, 791, and 891, have been re-
ported.1,8,57
Less frequently, hot spots and mutations, such as those
in codons 630, 790, 791, 891, and a 12 bp duplication be-
Table 2 - Multiple endocrine neoplasia type 2 (MEN2) genotype-phenotype correlations (Adapted from ref.13)
Exon Affected Codon Nucleotides Amino acid Phenotype MEN2 cases(%)
(wild-type → mutant) (wild-type → mutant)  
8 532, 533, 534 Ins AGG AGT GTG Ins Glu Glu Cys FMTC / HSCR Rare
533 GGC-TGC Gly-Cys FMTC
10 609 TGC-CGC Cys-Arg MEN2A / FMTC / HSCR 0-1
TGC-GGC Cys-Gly
TGC-TAC Cys-Tyr
611 TGC-AGC Cys-Ser MEN2A / FMTC 2-3
TGC-CGC Cys-Arg
TGC-TAC Cys-Tyr
TGC-TTC Cys-Phe
TGC-TGG Cys-Trp
618 TGC-AGC Cys-Ser MEN2A / FMTC / HSCR 3-5
TGC-CGC Cys-Arg
TGC-GGC Cys-Gly
TGC-TAC Cys-Tyr
TGC-TCC Cys-Ser
620 TGC-TTC Cys-Phe MEN2A / FMTC / HSCR 6-8
TGC-AGC Cys-Ser
TGC-CGC Cys-Arg
TGC-GGC Cys-Gly
TGC-TAC Cys-Tyr
TGC-TCC Cys-Ser
TGC-TTC Cys-Phe
TGC-TGG Cys-Trp
11 630 TGC-TAC Cys-Tyr MEN2A / FMTC 0-1
TGC-TCC Cys-Ser
TGC-TTC Cys-Phe
634 TGC-AGC Cys-Ser MEN2A 80-90
TGC-CGC Cys-Arg
TGC-GGC Cys-Gly
TGC-TAC Cys-Tyr MEN2A / FMTC
TGC-TCC Cys-Ser MEN2A / FMTC 80-90
TGC-TTC Cys-Phe
TGC-TGG Cys-Trp
635, 636, 637, 638 Ins CG AGC TGT GCC Ins Thr Ser Cys Ala MEN2A / FMTC Rare
637, 638, 639 Ins TGC CGC ACG Ins Cys Arg Thr MEN2A
648 GTC-ATC Val-Ile MEN2A
13 768 GAG-GAC Glu-Asp MEN2A / FMTC Rare
790 TTG-TTC Leu-Phe
TTG-TTT Leu-Phe
791 TAT-TTT Tyr-Phe
14 804 GTG-ATG Val-Met MEN2A / FMTC 0-1
GTG-TTG Val-Leu
15 883 GCT-TTT Ala-Phe MEN2B Rare
891 TCG-GCG Ser-Ala MEN2A / FMTC
16 918 ATG-ACG Met-Thr MEN2B / HSCR 3-5
922 TCC-TAC Ser-Tyr MEN2B Rare
MEN2A: Multiple endocrine neoplasia type 2A; MEN2B: Multiple endocrine neoplasia type 2B; FMTC: Familial medullary thyroid carcinoma; Ins:
Insertion
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tween codons 634 and 635, have been reported in FMTC
families, associated with an indolent form of MTC.8,64
Additionally, a 9 bp duplication in RET exon 8 creat-
ing a new cysteine residue in the extracellular portion of
the RET protein receptor was reported in a FMTC family,
possibly associated with HSCR. The affected case did not
present germline mutations in exons 10, 11, 13, 14, or 15
or somatic mutations in exons 11, 13, 15, and 16, suggest-
ing the neoplastic activity of this mutation.26
Recently, a new exon 8, Gly533Cys RET mutation was
reported in 76 FMTC carriers belonging to a family of
Spanish extraction in which 229 individuals were at risk.65
Multiple endocrine neoplasia type 2B (MEN2B)
A RET intracellular tyrosine kinase domain mutation,
Met918Thr, has been reported in 95% of MEN2B cases.56
In 4 families with MEN2B from Germany, United King-
dom, and Australia, an Ala883Phe substitution in exon 15
was described, comprising 4% of all MEN2B phenotypes
reported to date.8,13,56 Some rare mutations have been de-
scribed, such as Ser922Tyr and a double mutation in codon
804 and Tyr806Cys occurring in the same allele, which was
detected in a patient with MEN2B.13
Genotype-phenotype correlations in MEN2 have a ma-
jor and immediate impact in clinical medicine, since ge-
netic testing may differentiate RET carriers from
noncarriers. RET carriers should undergo total thyroidec-
tomy at ages that depend on the mutated codon,1,67 follow-
ing the MEN consensus (Table 3). Conversely, noncarriers
of the RET mutation should be excluded from annual clini-
cal follow-up, an expensive and stressing procedure for pa-
tients. In skillful surgical hands, the risks of neck surgery
are minimal even in children. False positives in genetic test-
ing are exceedingly low.1,10 All these data have generated
an international consensus on MEN regarding which MTC
patients should undergo surgery at ages preferably less than
5 years, depending on the mutated codon1,67 (Table 3). At
the time of writing, molecular DNA diagnosis in MEN2
has become an important tool to a) confirm clinical and
laboratory diagnosis of MTC; b) identify as early as pos-
sible mutant RET carriers in premalignant stages of the dis-
ease; and c) identify noncarrier family members and rule
them out for clinical follow-up.33
MODIFIER GENES IN RET EXPRESSION
Transgenic animal models expressing RET mutation are
used to better address the question of MEN2 MTC tumor
aggressiveness. Medullary thyroid carcinoma occurs in
transgenic lines with analogous pathology to that seen in
patients with MEN2. When the transgene codon 634 mu-
tation was introduced into 4 different genetic backgrounds
(BALB/c, C57BL/6J, FVB/N and CBA/ca), 65% of all ani-
mals developed MTC, showing incomplete penetrance.
None of the FVB/N transgenic progeny developed MTC,
14% of transgenic progeny BALB/c, 64% of C57BL/6J,
and 98% CBA/ca mice developed thyroid tumors by 10
months of age, indicating that incomplete tumor penetrance
could be modulated by genetic background. Furthermore,
tumors in the CBA/ca and C57BL/6J mice were signifi-
cantly larger than those in BALB/c transgenic mice. These
results are relevant to human MEN2 disease, because this
model system may be used to study genes modifying thy-
roid tumor penetrance in this dominantly inherited human
cancer syndrome.68
ROUTINE PROCEDURES IN MOLECULAR RET
DIAGNOSIS
Investigators working on studies dealing with humans
should follow the Helsinque decisions; thus, before collect-
ing blood samples for DNA analysis, projects should be
approved by local ethic committees, and patients involved
in research projects should sign a written informed con-
sent.
For genomic DNA extraction, a salting-out method is in-
dicated since it is a simple, low-cost procedure.69 For ampli-
Table 03 - Surgical management of multiple endocrine
neoplasia2 based on international multiple endocrine
neoplasia consensus (Adapted from ref.1)
Risk 3 level: Highest risk of development of an aggressive and early form
of medullary thyroid carcinoma. Children with multiple endocrine neoplasia
2B or mutation carriers in codons 883, 918 or 922, should be submitted to
total thyreoidectomy during the first six months of life, preferentially a the
first month as microscopic medullary thyroid carcinoma with metastases
may occur in the first months of life. Total thyreoidectomy should be
performed in association with an extensive ressection of the neck lymph
nodes, mainly including central neck lymph nodes.
Risk 2 level: High risk to present an aggressive form of medullary thyroid
carcinoma. Children carrying RET mutation in codons 611, 618, 620 or 634
should be submitted to total surgery before 5 years of age. Total
thyreoidectomy should be performed in association with removal of thyroid
posterior capsule and dissection of central lymph nodes.
Risk 1 level: Moderate risk to develop aggressive forms of medullary thyroid
carcinoma. Children carrying mutations in codons 609, 768, 790, 791 804
or 891 should be also submitted to total thyreoidectomy. There are three
alternatives related to ages for surgical procedures. First, some authors
indicate patients should be operated before age 5, as in risk 2 level. Others
suggest 10 years of age as a cut-off for surgical indication. The third
alternative is waiting for abnormal basal or stimulated calcitonin values for
indicating surgery. Biological behaviors of these tumors are variable, but
frequently present a late and indolent evolution. It is worthwhile to note that
metastases or death were reported in patients carrying all these genotypes.
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Figure 1 - Electropherograms showing five different types of RET mutations in MEN2, using a DNA sequencer (ABI 310 DNA Sequencer - Applied
Biosystems, USA)
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fication of genomic DNA, fragments of interest are usually
amplified using the polymerase chain reaction (PCR) strat-
egy.70 Primers should contain flanking sequences of intron-
exon boundaries for adequate RET proto-oncogene analy-
sis, and if a laboratory chooses the DGGE (denaturing gra-
dient gel electrophoresis) strategy for screening mutation
analysis, primers may also contain a 50bp GC-clamp cou-
pled in one of the sequences.71–73 The presence of adequate
amplified sequences are confirmed using runs in 1% agarose
gel electrophoresis stained with ethidium bromide. After ob-
taining PCR products, direct sequencing analysis (the gold-
standard method for RET mutation diagnosis) should be per-
formed in all MEN2 index cases. Once the genotype of the
RET mutation in the index case is known, it may be used as
intrafamilial positive control. For at-risk family members,
screening methods may be used. In this latter alternative, it
is possible to use DGGE, single-strand conformation poly-
morphism (SSCP) or restriction enzyme approaches.72–77 The
DGGE and SSCP techniques are based on differential mi-
gration mobilities in polyacrylamide gel. Thus, applying
these techniques, it is possible to discriminate between mu-
tant carriers and noncarriers. Different electrophoretic mi-
gration patterns are influenced by denaturant substances,
such as urea and formamide (in DGGE) or heteroduplex for-
mation (in SSCP). Particularly when screening large MEN2
families, these methods are very useful; for instance, using
DGGE, one might analyze 16 exons in 24 hours. Restric-
tion enzymes may possibly be useful in genetic screening
for RET mutations, as mutations create or destroy restric-
tion sites recognizable by endonucleases. However, this
method should only be applied to confirm DGGE or SSCP
findings, considering that interferences may occur as follows:
a) inadequate recognition of restriction site and consequently
no defined band in agarose gel electrophoresis or b) incom-
plete discrimination of amplified sequences with similar base
pair sizes.77,78
Using direct genetic sequencing analysis (the gold-
standard method), DNA fragments of interest are sequenced
by enzymatic or chain termination, as described by Sanger
in 1977.71 In this technique, each primer must be added
separately to sense and missense reaction tubes, with a
commercial buffer (Big Dye Terminator Cycle Sequencing,
Applied Biosystems, Foster City, USA) and processed in a
thermocycler. After the sequencing reaction, samples are
purified with isopropanol and ethanol and diluted in blue
dextran buffer with deionized formamide. The sequencing
products are then denatured at 90 ºC for 2 minutes, imme-
diately cooled, and applied into a specific electrophoresis
polymer for the DNA sequencer. Using these procedures,
good reproducibility is usually obtained, avoiding the need
of a confirmation reaction. Figure 1 illustrates examples
of electropherograms showing MEN-2 RET mutations.
CONCLUSIONS
Before RET molecular diagnosis was possible, first-de-
gree relatives of MEN2 patients (who have a 50% chance
of being carriers) were clinically and biochemically fol-
lowed up every 12 months for MTC, PHEO, and HPT. In-
dividuals had to be annually evaluated from 6 years of age
on. Thus, basal and stimulated calcitonin serum levels were
measured in these individuals, as well as serum PTH, cal-
cium, and serum/urinary cathecolamines.8,22,67 The sensitiv-
ity of these tests was variable, and as a consequence, MTC
was usually diagnosed late. This prolonged follow-up was
expensive; individuals at risk were maintained in a stress-
ing condition; survival rates were diminished, and cure was
almost never achieved due to late MEN2 diagnosis and high
prevalence of lymph node metastases,.79,80
At the time of writing, because almost 95% of affected
MEN2 patients harbor a mutation, genetic diagnosis of
MEN2 has become a great success story in the manage-
ment of patients that are RET mutation carriers.67,81 Direct
DNA sequencing is of course the gold-standard method for
RET mutation analysis and should be performed routinely
in all index cases and possibly in all suspected cases. Al-
ternatively, once the presence of a RET mutation is ascer-
tained, screening methods may be used in analyzing fam-
ily members at risk. Whatever DNA method is used, early
RET mutation analysis provides information to clinicians
and surgeons allowing them to make adequate surgical de-
cisions. As a consequence of these procedures, mortality
rates in MEN2 have dropped from up to 20% in 1993 to
5% currently.1 Finally, early RET mutation analysis should
be performed in all MTC and PHEO cases, as suggested
by the MEN consensus.1
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RESUMO
Toledo SPA, Cortina MA, Toledo RA, Lourenço, DM. Im-
pacto da análise do proto-oncogene RET na conduta clíni-
ca da neoplasia endócrina múltipla tipo 2. Clinics.
2006:61(1);59-70.
A neoplasia endócrina múltipla tipo 2 (NEM2) é caracte-
rizada pela ocorrência do carcinoma medular de tireóide
(CMT), hiperparatiroidismo primário (HPT) e feocromo-
citoma (FEO).1-12 Desde 1993, quando as primeiras muta-
ções do tipo missense no proto-oncogene RET (RET), as-
sociadas a NEM2 foram identificadas, 46 diferentes muta-
ções causadoras de doenças foram descritas.13-17 Como há
uma forte correlação genótipo-fenótipo na NEM2, a
detecção de mutações no RET adquiriu grande impacto no
tratamento precoce do CMT e NEM2. A NEM2 persiste
como uma doença subdiagnosticada e/ou tardiamente
diagnosticada em várias áreas geográficas do globo. A aná-
lise de mutações do RET deve ser realizada em todas os
casos de NEM2 e atualmente, a tireoidectomia total
profilática é indicada para todos os indivíduos portadores
de mutações no RET.1 Para a grande maioria dos portado-
res de mutações gaméticas ativadoras no RET este proce-
dimento cirúrgico é indicado nos primeiros anos de vida,
promovendo melhora na qualidade de vida, aumento da
sobrevida ou mesmo levando à cura definitiva.1 Discutimos
nesta revisão, o impacto da análise do proto-oncogene RET
na conduta clínica da neoplasia endócrina múltipla tipo 2.
Além disso, o diagnóstico molecular do RET fornece à clí-
nicos e cirurgiões a mais valiosa das informações, permi-
tindo indicação de tireoidectomia total profilática.
UNITERMOS: Neoplasia Endócrina. NEM2. Proto-
oncogene RET. Feocromocitoma. Hiperparatireoidismo.
HSCR. CMT. CMT-F.
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